Bayer calls for deregulation as healthcare reform cost it €300 million
This article was originally published in Scrip
Instead of putting the squeeze on innovation, Bayer wants to see more deregulation and reforms that stimulate competition, the firm told Scrip. Global healthcare reform cost the firm €300 million in 2011, with the biggest impact coming from the US and Germany, it said.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.